Clinical trials: Paclitaxel, completed
Locally Recurrent Breast Cancer, Metastatic Breast Cancer
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens.
- Trial name
- BEACON (NCT01492101)
- Testing
- NKTR-102, Treatment of Physician's Choice (TPC)
- Where
- 153 sites in United States, Belgium and 9 more
- Volunteers
- 852 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining peripheral stem cell transplantation with chemotherapy may kill more tumor cells.
- Trial name
- NCT00002837
- Testing
- Filgrastim (G-CSF), Cyclophosphamide, Doxorubicin Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis
This study will assess the efficacy and safety of Avastin combined with first li ne paclitaxel-carboplatin (cohort 1) or second line Tarceva (cohort 2) in patien ts with non-squamous non-small cell lung cancer with asymptomatic…
- Trial name
- NCT00800202
- Testing
- bevacizumab [Avastin], carboplatin, erlotinib [Tarceva]
- Where
- 25 sites in France
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
This phase I/II trial is designed to efficiently identify the regimen limiting toxicity (RLT) and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent indoximod when administered in combination with…
- Trial name
- NCT02077881
- Testing
- Nab-Paclitaxel, Gemcitabine, Indoximod
- Where
- 11 sites in United States
- Volunteers
- 157 people
- Sponsor
- NewLink Genetics Corporation
Lung Cancer, Non-Small Cell
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
The Phase I part of the study will identify the doses of pazopanib and paclitaxel that can be administered safely in combination. The Phase II part of the study will not be progressed as documented in Protocol Amendment 01.
- Trial name
- NCT00866528
- Testing
- pazopanib, paclitaxel
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Stage IV Non-small Cell Lung Cancer
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
To define Phase 1/2 Maximum Tolerated Dose Study of Belinostat (PXD-101) in Combination with Paclitaxel plus Carboplatin in Chemotherapy-Naive Patients with Stage IV Non-Small-Cell Lung Cancer (NSCLC).
- Trial name
- NCT01310244
- Testing
- Belinostat, Carboplatin, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Breast Cancer, Taste Disorders
Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.
Taste disorders in cancer patients during chemotherapy could be consider as multifactorial disease, it is related with changes of food consumption.
- Conditions
- Breast Cancer, Taste Disorders, Dysgeusia, Ageusia
- Trial name
- NCT04543175
- Testing
- Taste disorder´s test
- Where
- Mexico
- Volunteers
- 106 people
- Sponsor
- Hospital General de Mexico
Uterine Cancer
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy…
- Trial name
- NCT00584857
- Testing
- Paclitaxel ,Carboplatin , Megesterol Acetate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Coronary Stenosis
Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease
The purpose of this study is to evaluate the efficacy and safety of RESTORE Paclitaxel eluting balloon in the treatment of Chinese patients with coronary heart disease and small vessel lesions in comparison with RESOLUTE…
- Trial name
- NCT02946307
- Testing
- Restore DEB（dimeter>2.00 mm）, Resolute DES, Restore DEB（dimeter:2.00 mm）
- Where
- 12 sites in China
- Volunteers
- 240 people
- Sponsor
- ZhuHai Cardionovum Medical Device Co., Ltd.
HER2-negative Metastatic Breast Cancer, HER2-positive Circulating Tumor Cells
DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs
The HER2 status in breast cancer patients may change during the course of the disease. In 30% of initially HER2-negative patients with circulating tumor cells (CTC), HER2-positive CTCs can be detected in peripheral blood…
- Trial name
- DETECT III (NCT01619111)
- Testing
- standard chemo- or endocrine therapy, standard chemo- or endocrine therapy + Lapatinib
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Prof. Wolfgang Janni
Coronary Artery Disease
Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia
To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon
- Trial name
- SCBDNMAL (NCT04017364)
- Testing
- PCB PTCA, SCB PTCA
- Where
- 6 sites in Malaysia
- Volunteers
- 70 people
- Sponsor
- InnoRa GmbH
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
This research study examines the use of Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) in patients with lung cancer. Abraxane is a chemotherapy approved to treat patients with breast cancer.
- Trial name
- NCT01620190
- Testing
- Laboratory Biomarker Analysis, Paclitaxel Albumin-Stabilized Nanoparticle Formulation
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.
This 2 arm study will compare the efficacy and safety of Tarceva plus Avastin, and chemotherapy plus Avastin, in the first-line treatment of patients with advanced non-small cell lung cancer.
- Trial name
- NCT00531960
- Testing
- Erlotinib, Bevacizumab, Standard platinum-based chemotherapy
- Where
- 57 sites in Australia, Belgium and 11 more
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Peripheral Artery Disease
Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery
Objective of the REAL PTX trial is to compare paclitaxel-eluting stents to paclitaxel-eluting balloons for treating symptomatic peripheral artery disease of the femoropopliteal artery.
- Trial name
- NCT01728441
- Testing
- Paclitaxel Eluting Stent, Paclitaxel Eluting Balloon
- Where
- 5 sites in Belgium, Germany
- Volunteers
- 150 people
- Sponsor
- Provascular GmbH
Bowel Obstruction, Ovarian Cancer
Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer
Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal.
- Conditions
- Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- CEBOC (NCT07648745)
- Testing
- Cediranib
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Prof Gordon Jayson
Non-Small Cell Lung Cancer, Neoplasm Metastasis
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Rationale: Overexpression of epidermal growth factor receptor (EGFR) has been observed in kidney, prostate, colon, lung, breast, and other cancers, and is often associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer
- Trial name
- NCT00034346
- Testing
- ABX-EGF, paclitaxel, carboplatin
- Volunteers
- 194 people
- Sponsor
- Amgen
Lean Body Mass, Cannabis
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
An intervention study on the effect of cannabidiol on lean body mass in cancer patients receiving chemotherapy, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark.
- Conditions
- Lean Body Mass, Cannabis, Cancer, Nausea
- Trial name
- NCT04585841
- Testing
- Cannabidiol
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- University of Copenhagen
Carcinoma of the Cervix, Stage IVB
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely…
- Trial name
- BEATcc (NCT03556839)
- Testing
- Atezolizumab, Bevacizumab, Cisplatin/Carboplatin
- Where
- 72 sites in United States, France and 6 more
- Volunteers
- 410 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Triple Negative Breast Cancer
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
This multicenter, randomized, double-blind study evaluated the efficacy, safety, and pharmacokinetics of atezolizumab (MPDL3280A) administered with nab-paclitaxel compared with placebo in combination with nab-paclitaxel in…
- Trial name
- NCT02425891
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-Paclitaxel
- Where
- 247 sites in United States, Argentina and 38 more
- Volunteers
- 902 people
- Sponsor
- Hoffmann-La Roche
Femoral Artery Stenosis, Popliteal Artery Stenosis
Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries
The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of…
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- LEVANT 2 (NCT01412541)
- Testing
- Standard Uncoated Angioplasty Balloon, Moxy Drug Coated Balloon
- Where
- 54 sites in United States, Austria and 2 more
- Volunteers
- 532 people
- Sponsor
- C. R. Bard
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.